November 1, 2012
Dainippon Sumitomo Pharma (DSP) announced on October 31 that the US FDA has accepted two supplemental new drug applications (sNDAs) for the schizophrenia treatment Latuda (lurasidone), which is currently marketed in the US, for depressive episodes associated with bipolar I...read more